Format

Send to

Choose Destination
Trends Mol Med. 2014 Jul;20(7):385-93. doi: 10.1016/j.molmed.2014.03.002. Epub 2014 Apr 3.

Extracellular vesicles: emerging targets for cancer therapy.

Author information

1
Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK.
2
Department of Neurology, Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, Boston, MA 2129, USA.
3
Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK. Electronic address: matthew.wood@dpag.ox.ac.uk.

Abstract

Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, are released by almost all cell types, including tumour cells. Through transfer of their molecular contents, EVs are capable of altering the function of recipient cells. Increasing evidence suggests a key role for EV mediated intercellular communication in a variety of cellular processes involved in tumour development and progression, including immune suppression, angiogenesis, and metastasis. Aspects of EV biogenesis or function are therefore increasingly being considered as targets for anticancer therapy. Here, we summarise the current knowledge on the contributions of EVs to cancer pathogenesis and discuss novel therapeutic strategies to target EVs to prevent tumour growth and spread.

KEYWORDS:

cancer therapy; exosomes; extracellular vesicles; metastasis; microvesicles; tumour microenvironment

PMID:
24703619
PMCID:
PMC4082760
DOI:
10.1016/j.molmed.2014.03.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center